iFR-guided Revascularization in STEMI

ST Segment Elevation Myocardial Infarction Clinical Trial

— WAVE  

Official title:

iFR-guided Revascularization of Non-culprit Lesion in Patients With ST-segment Elevation Myocardial Infarction and Multivessel Disease (WAVE Registry): Long-term Outcome.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03561389
• Other study ID #: 76/2018 CE Lazio1
• Status: Recruiting
• Start date: May 1, 2018
• Est. completion date: March 31, 2020

Study information

• Verified date: January 2020
• Source: Azienda Ospedaliera San Camillo Forlanini
• Contact: Carmine Musto, PhD, MD
• Phone: +393396361601
• Email: cmusto[@]hotmail.it
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Functional assessment of non-culprit lesions during percutaneous coronary intervention (PCI) in patients with acute coronary syndrome could improve risk stratification and long-term prognosis. It was previously demonstrated the diagnostic accuracy of instantaneous wave-free ratio (iFR) in functional assessment of non-culprit lesions in multivessel patients with ST-segment elevation myocardial infarction (STEMI), also highlighting the intralesional reproducibility of both fractional flow reserve (FFR) and iFR between baseline and staged. In this study the investigators aimed to verify the clinical impact on long-term outcome of iFR assessment in the acute multivessel setting.

Description:

Background - Approximately 40-50% of patients undergoing primary PCI for STEMI have an occasional finding of multivessel coronary artery disease on angiography. In this setting there is a general consensus in the treatment of the culprit lesion (infarct related artery - IRA), while the literature provides contrasting evidence on the preventive treatment of non-culprit coronary lesions (not IRA). Four major randomized trials have, in fact, compared a complete revascularization strategy versus culprit-only revascularization during primary PCI: PRAMI trial, CULPRIT trial, DANAMI-3-PRIMULTI trial and Compare-Acute trial. Although all of these studies demonstrated a benefit in the composite cardiovascular end point in patients undergoing complete revascularization, no statistically significant difference in mortality was found. Therefore, at present, there is no definite evidence on the efficacy of non culprit lesion treatment on mortality and re-MI in patients with STEMI.

The recent guidelines of the European Society of Cardiology 2017 suggest however to evaluate the complete revascularization in multivessel patients before discharge (class IIa, level A). Previous randomized trials such as Compare-Acute study and DANAMI-3-Primulti showed that a complete revascularization strategy guided by FFR, during primary PCI, is associated with a significantly lower risk of cardiovascular events in patients with multivessel disease.

Furthermore, other studies demonstrated that an iFR-guided coronary revascularization is not inferior to FFR-guided revascularization in patients with stable coronary artery disease, whereas, it significantly reduces the overall duration of the procedure. The WAVE study recently demonstrated the diagnostic accuracy of iFR in functional assessment of non-culprit lesions in multivessel patients with STEMI, also highlighting the intralesional reproducibility of both FFR and iFR between baseline and staged. To date, however, there are no studies in the literature that have verified the long-term clinical impact of an iFR-guided revascularization during primary PCI for STEMI patients with multivessel coronary artery disease.

Aim of the study - Multicenter, observational registry to evaluate the long-term clinical impact of an iFR assessment of the non-culprit lesions during primary PCI for STEMI patients with multivessel coronary artery disease.

Methods - patients undergoing primary PCI for STEMI and presenting multivessel disease (at least another coronary stenosis ≥ 50% in addition to the culprit one on QCA analysis) will be enrolled. At the end of the revascularization procedure of the culprit lesion, the functional assessment of the non-culprit lesion will be performed through the use of iFR. In the case of iFR ≤ 0.89, the functionally critical lesion treatment will be performed during the same PCI procedure or staged (at the discretion of the operator and the center). On the other hand, patients with iFR> 0.89 will instead be directed towards a conservative approach with the implementation of clinical-instrumental follow-up.

A clinical follow-up will be performed in all patients by telephone interviews or outpatient visits at 12, 24 and 36 months from the index procedure.

The primary endpoint of the study is represented by the occurrence of Target Lesion Failure (TLF), a composite of cardiovascular death, non-fatal myocardial infarction, and ischemia-driven revascularization of the vessel previously assessed with iFR.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: March 31, 2020
• Est. primary completion date: March 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• age> 18 years

• 12-hour chest pain with ST segment elevation greater than 0.1 mV in at least two contiguous leads treated with primary PCI

• presence of at least one non-culprit lesion with =50% stenosis in an epicardial vessel =2.5 mm

• informed consent signed

Exclusion Criteria:

• ejection fraction = 30%

• presence of moderate / severe valvulopathies

• electrical instability and hemodynamics at the end of the index procedure (Killip III-IV class)

• TIMI flow <3 at the end of the index procedure

• previous myocardial infarction in the same territory of the non-culprit lesion

• previous coronary artery bypass grafting on the vessel undergoing functional assessment by iFR

• Inability to provide informed consent to the study

Related Conditions & MeSH terms

• Infarction
• Myocardial Infarction
• ST Elevation Myocardial Infarction
• ST Segment Elevation Myocardial Infarction

Locations

Country	Name	City	State
Italy	Ospedale San Camillo	Roma

Sponsors (1)

Lead Sponsor	Collaborator
Azienda Ospedaliera San Camillo Forlanini

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Target Lesion Failure (TLF)	A composite of cardiovascular death, non-fatal myocardial infarction, and ischemia-driven revascularization of the vessel previously assessed with iFR	12 months